Arch Therapeutics (OTCMKTS:ARTH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday, TipRanks reports. They currently have a $2.00 price target on the biotechnology company’s stock.
Separately, Zacks Investment Research raised Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research note on Thursday.
ARTH opened at $0.18 on Thursday. Arch Therapeutics has a fifty-two week low of $0.12 and a fifty-two week high of $0.38. The business has a 50-day moving average of $0.20 and a 200-day moving average of $0.21.
About Arch Therapeutics
Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.
Featured Story: What’s a Black Swan?
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.